Hikal Limited has informed the Exchange regarding Earnings press release on the results of the company for the quarter ended June 30, 2025.
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hikal Limited reported weak Q1 FY26 results with consolidated revenue of Rs 380 crore, down from Rs 407 crore in Q1 FY25. EBITDA fell sharply to Rs 25 crore (margin 6.5%) from Rs 58 crore (margin 14.3%) a year ago. The company slipped into a loss with a negative PAT of Rs (23) crore versus a profit of Rs 5 crore in Q1 FY25, translating to an EPS of Rs (1.84). The Pharmaceuticals segment, which contributes 53% of revenue, was hit hardest at Rs 203 crore with an EBIT margin of -12.9%, due to customer offtake being deferred after the USFDA issued an Official Action Indicated (OAI) classification for its Bangalore facility on May 22, 2025. The Crop-Protection segment was largely flat at Rs 178 crore (EBIT margin 9.7%). Management remains confident of meeting full-year FY26 guidance, expecting a meaningful recovery in H2 FY26.
Shareholders should brace for near-term pain: a quarterly loss and sharply lower margins are a clear negative. The USFDA OAI status is the key overhang — until customer offtake resumes and the regulatory issue is resolved, stock sentiment may remain weak. However, management's reaffirmation of FY26 guidance and successful clearance of other global audits (ANVISA, PMDA) offer some support for a longer-term recovery story.